Continuous Outcome Estimation in N-of-1 Trials for Accelerated Decision-Making in Neurological Conditions

Study Design

A new study by Victoria Defelippe and colleagues demonstrates that continuous Bayesian outcome estimation in N of 1 trials can accelerate clinical decision-making while maintaining statistical rigor. The research examined whether treatment effects can be evaluated before the pre-specified end of a trial, potentially reducing trial duration and patient burden without sacrificing certainty.

The study combined two approaches: (1) simulation of an N of 1 trial in severe epilepsy, and (2) reanalysis of three previously conducted N-of-1 trials in neurological conditions. Treatment effects were evaluated continuously as new data accumulated using Bayesian hypothesis testing, with outcomes compared against a minimally clinically important difference (MCID) threshold defined as a 30% reduction in seizure frequency.

Key Results

• Continuous outcome estimation could reduce trial duration by approximately 9.5% to 35% in two of the four examples without sacrificing certainty in treatment effect estimates.

• The point at which strong Bayesian evidence emerged did not always coincide with the point at which clinically meaningful effects became likely, highlighting the importance of integrating statistical evidence with clinical thresholds.

• Continued data collection and treatment alternation improved precision and confidence in effect estimates, even after early evidence emerged, supporting the value of sequential analysis.

  
  

Key Takeaway

Continuous Bayesian outcome estimation can make N of 1 trials shorter, more efficient, and more responsive to individual patient needs without compromising statistical rigor. By updating evidence as data accumulate and integrating clinical thresholds with statistical evidence, researchers and clinicians can make faster, more confident treatment decisions in complex neurological conditions.

Why This Matters for N of 1 Research

This study has important implications for both clinical practice and N of 1 trial methodology. For clinicians treating patients with high-burden conditions like severe epilepsy or complex neurological disorders, early termination based on strong evidence could reduce unnecessary treatment exposure, decrease patient burden from prolonged trial participation, and allow faster implementation of effective interventions.

For researchers, the study provides a methodological framework that bridges statistical evidence and clinical meaningfulness. By integrating Bayesian hypothesis testing with MCID-based interpretation, investigators can design more efficient trials that are both statistically rigorous and clinically relevant. This approach is particularly valuable for rare and ultra-rare  conditions where recruitment is difficult and individual patient burden is substantial.

The work also highlights a fundamental principle of N of 1 trial design: there is no inherent requirement to wait until a pre-specified endpoint to make treatment decisions. Instead, continuous outcome estimation allows for adaptive decision-making that responds to emerging evidence while maintaining statistical integrity.

About the Research Team

This study represents collaboration among leading experts in N of 1 trial methodology and Bayesian statistics. Victoria Defelippe leads the effort, working alongside renowned statistician Eric-Jan Wagenmakers (University of Amsterdam), paediatric neurologist Kees P.J. Braun, and colleagues Floor E. Jansen and Willem M. Otte. The team brings together expertise in epilepsy research, Bayesian inference, and personalised trial design across multiple European institutions.

Where to Read the Full Paper

The complete study has been published in Epilepsia, February 2026, under the title 'Continuous outcome estimation in N-of-1 trials for accelerated decision-making.' The paper provides detailed methodological descriptions, simulations, and reanalysis of the three clinical cases, offering valuable guidance for researchers designing their own N of 1 trials.